Role and mechanisms of exercise therapy in enhancing drug treatment for glioma: a review

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: April 30, 2025

Gliomas, particularly glioblastoma (GBM), are among the most aggressive and challenging brain tumors to treat. Although current therapies such as chemotherapy, radiotherapy, targeted treatments have extended patient survival some extent, their efficacy remains limited is often accompanied by severe side effects. In recent years, exercise therapy has gained increasing attention an adjunctive treatment in clinical research settings. Exercise not only improves patients’ physical function cognitive abilities but may also enhance of conventional drug modulating immune system, suppressing inflammatory responses, improving blood-brain barrier permeability. This review summarizes potential mechanisms glioma treatment, including enhancing surveillance through activation natural killer (NK) cells T cells, penetration function. Additionally, studies suggest that can synergize with chemotherapy immunotherapy, outcomes while reducing drug-related application patients still exploratory phase, existing evidence indicates its significant value approach, become a new standard future.

Language: Английский

Exploring susceptibility and therapeutic targets for kidney stones through proteome-wide Mendelian randomization

Human Molecular Genetics, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 7, 2024

Given the high recurrence rate of kidney stones, surgical lithotripsy and stone removal are not ultimate treatments for stones. There's an urgent need to explore genetic mechanisms behind susceptibility stones identify potential targets prevention, reduce renal damage caused by recurrent formation. In this study, we screened 4548 circulating proteins using proteome-wide Mendelian Randomization (MR) find with a causal relationship risk. Additionally, association study (PWAS) colocalization analysis were used validate prioritize candidate proteins. Moreover, downstream analyses including single-cell analysis, enrichment protein-protein interaction (PPI), druggability conducted on causally related further as drug targets. Ultimately, 22 target associated risk identified. Six plasma (COLGALT1, CLMP, LECT1, ITIH1, CDHR3, CPLX2) negatively correlated risk, while overexpression 16 (GJA1, STOM, IRF9, F9, TMPRSS11D, ADH1B, SPINK13, CRYBB2, TNS2, DOCK9, OXSM, MST1, IL2, LMAN2, ITIH3, KLRF1) increased Based PWAS results, classified into 3 tiers: CPLX2, LMAN2 tier 1 most compelling evidence, ITIH3 2 proteins, rest Enrichment PPI showed that mainly affect occurrence through leukocyte activation cell junction assembly. Druggability suggested ITIH1 have targets, drugs evaluated molecular docking. summary, employed multiple analytical methods screen providing new insights treatment prevention.

Language: Английский

Paromomycin targets HDAC1-mediated SUMOylation and IGF1R translocation in glioblastoma

Frontiers in Pharmacology, Journal Year: 2024, Volume and Issue: 15

Published: Dec. 11, 2024

Objective This study investigates the effects of Paromomycin on SUMOylation-related pathways in glioblastoma (GBM), specifically targeting HDAC1 inhibition. Methods Using TCGA and GTEx datasets, we identified genes associated with GBM prognosis. Molecular docking analysis suggested as a potential inhibitor. In vitro assays U-251MG cells were performed to assess Paromomycin’s cell viability, SUMOylation gene expression, IGF1R translocation using CCK8 assays, qRT-PCR, immunofluorescence. Results treatment led dose-dependent reduction colony formation, migration. It modulated SUMO1 expression decreased nuclear translocation, an effect reversible by inhibitor Trochostatin A (TSA), suggesting involvement SUMO1-regulated pathways. Conclusion highlights therapeutic agent for HDAC1-mediated influencing warranting further investigation its clinical application.

Language: Английский